Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan

Published:2024-07 Issue: Volume: Page:
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Taniguchi Toshibumi^ORCID,Homma Tomoyuki,Tamai Yoichi,Arita Yoshifumi^ORCID,Fujiwara Masakazu^ORCID,Kuroishi Naho^ORCID,Sugiyama Keiji,Kanazu Shinichi,Maruyama Atsushi

Publisher

Elsevier BV

Reference41 articles.

1. Coronavirus disease-2019 in the immunocompromised host;Bertini;Clin Chest Med,2023

2. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study;Evans;Lancet Reg Health Eur,2023

3. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada;Bahremand;Lancet Reg Health Am,2023

4. Factors associated with COVID-19-related death using OpenSAFELY;Williamson;Nature,2020

5. Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan;Nomoto;J Infect Chemother,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP